AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is conducting a study titled ‘An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)’. The study aims to explore the biological effects of these treatments in prostate cancer, which could provide significant insights into their efficacy and safety.
Intervention/Treatment: The study tests the effects of Saruparib (AZD5305) and Darolutamide, both alone and in combination. Saruparib is administered once daily, while Darolutamide is given twice daily. These drugs are intended to be used before prostate surgery to assess their impact on cancer cells.
Study Design: This is an open-label, randomized, phase I study with a parallel intervention model. There is no masking, and the primary purpose is basic science. Participants are allocated to different treatment arms to evaluate the effects of the drugs individually and in combination.
Study Timeline: The study began on September 21, 2023, and is currently recruiting participants. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
Market Implications: This study could influence AstraZeneca’s stock performance by potentially expanding its prostate cancer treatment portfolio. Positive outcomes might boost investor confidence and position AstraZeneca favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.